Abstract Bronchogenic carcinoma is the leading cause of malignancy-related mortality in the United States, with an overall 5-year survival rate of less than 15%. This aggressive behavior re¯ects, among other traits, the capacity of the tumor to evade normal host immune defenses, and to induce a pro-angiogenic environment. A central feature of any immune response toward tumors is the recruitment of speci®c immune cell populations. In the present study we investigated the in®ltration of monocytes in human specimens of non-small-cell lung cancer (NSCLC). The presence of macrophages in NSCLC tumors was documented by immunohistochemistry. In vitro chemotaxis assays demonstrated higher monocyte chemotactic activity in NSCLC tumor homogenates than in normal lung tissue. We next investigated the expression of CC chemokines within specimens of NSCLC tumors. Levels of the CC chemokines were higher in NSCLC tumor tissue than in normal lung tissue. Immunolocalization showed that the cells associated with antigenic CC chemokines were the malignant tumor cells, as well as occasional stromal cells. Maximal inhibition of monocyte chemotaxis induced by NSCLC in vitro occurred in the presence of neutralizing antibodies to MCP-1 and MIP-1b. On follow-up of 15 patients in whom we quanti®ed macrophage in®ltration, we found that those with recurrence of disease had higher levels of macrophage in®ltration in their initial tumors. However, the functional signi®cance of CC-chemokine-mediated macrophage in®ltration into NSCLC remains to be determined.
Introduction
Eorts at improving the poor prognosis of patients with non-small-cell lung cancer (NSCLC) depend, in part, upon a better understanding of the biology of lung cancer. One important aspect of this biology is the nature of interactions between malignant cells and the associated host cells within the tumor. Macrophages may constitute an important interface between tumor cells and the immune system. The role of macrophages in cancer has been studied with con¯icting results. For example, dierent studies have found that macrophages can promote [1, 24, 35] , or inhibit [24, 27] tumor growth, or exert cytostatic activity on growing tumor cells [3] . In this study we investigated the nature of macrophage in®ltration into tumors, and hypothesize that tumorassociated macrophages may be recruited by local expression of macrophage chemotactic factors in NSCLC. Evidence suggesting active recruitment of macrophages to the site of a tumor would support the hypothesis that macrophages are capable of promoting tumor growth.
The chemokines represent a superfamily of chemotactic cytokines that recruit and activate sub-popula-tions of leukocytes. They are further classi®ed into CC, CXC, CX 3 C, and C families based upon the con®gura-tion of cysteine amino acid residues in the NH 2 terminus. Macrophage recruitment is induced primarily by members of the CC chemokine family.
In the present study we evaluated patients with NSCLC at the University of Michigan Medical Center. We investigated the in®ltration of macrophages relative to the content of speci®c CC chemokines (MCP-1, MIP1a, MIP-1b, and RANTES) from the NSCLC tissue. Our results demonstrated that NSCLC tumors are markedly in®ltrated with macrophages. Chemotaxis assays were performed with tumor homogenates to determine their ability to induce monocyte migration. These results demonstrated marked chemotactic activity in tumor homogenates relative to that in normal lung tissue. Furthermore, we found higher levels of CC chemokines in tumor tissue than in normal lung tissue. Immunolocalization of CC chemokines in NSCLC tissue revealed tumor cell localization of CC chemokine protein. Enumeration of in®ltrating macrophages revealed a strong correlation with the levels of CC chemokines present in the corresponding tumor homogenate. Chemotaxis assays in the presence and absence of speci®c neutralizing antisera revealed that inhibition of chemotaxis was maximal in the presence of neutralizing antibodies to MCP-1 and MIP-1b.
Our ®ndings suggest that the presence of macrophages in advanced human lung cancer is due to the expression of CC chemokines in the tumor. However, the activation of these immune cells may be inadequate for a successful immune response against the tumor. In addition, it is possible that recruited macrophages bene®t the tumors by elaborating molecules such as growth factors or angiogenic factors.
Materials and methods

Tissue specimens
Lung tissue specimens were obtained in a prospective fashion from consecutive patients undergoing thoracotomy for suspected primary bronchogenic carcinoma. All studies involving human tissues received prior approval of the University of Michigan's Institutional Review Board in accordance with the declaration of Helsinki. Normal lung specimens were obtained from a resected area of normal lung distal to the tumor. After recovery from the operating room, tissue samples were sectioned and two 6-mm 3 sections of tissue were homogenized in Complete anti-protease buer (Boehringer Mannheim, Mannheim Germany) and sonicated. The aqueous extract of the tumor was frozen for later analysis by speci®c enzyme-linked immunosorbent assay (ELISA). Additional portions of some specimens were ®xed in 4% paraformaldehyde for 24 h, transferred to 70% ethanol, and subsequently embedded in paran. Pathological diagnoses were determined by a review of specimen slides by University Hospital pathologists. Only specimens with a ®nal diagnosis of primary bronchogenic carcinoma were included in our study, with further classi®cation of squamous cell or adenocarcinoma histology.``Normal'' specimens were excluded from use in chemotaxis assays if the corresponding histological section revealed tumor or signi®cant in¯ammation as indicated by leukocyte in®ltration.
Reagents
Polyclonal antisera speci®c for human MCP-1, MIP-1a and MIP1b were produced in our laboratories by the immunization of rabbits with human recombinant MIP-1a and MIP-1b (R&D Systems, Minneapolis, Minn.) or MCP-1 (Pepro Tech Inc., Rocky Hill, N.J.), in multiple intradermal sites with complete Freund's adjuvant. The speci®city of each of these antibodies was assessed by Western blot analysis against a panel of other human recombinant cytokines. A commercial neutralizing polyclonal goat anti-(human RANTES) antibody was also employed (R&D Systems, Minneapolis, Minn.). All antibodies were speci®c in a sandwich ELISA, and without cross-reactivity to a panel of 12 human recombinant interleukins (IL), including interleukin-1 receptor antagonist protein (IRAP), IL-1, IL-2, IL-4, IL-6, tumor necrosis factor a (TNFa), interferon c (IFNc), and members of the CXC chemokine family. The neutralizing capacity of our rabbit antibodies has been characterized and a 1:1000 dilution of antiserum will neutralize the chemotactic activity of 30 ng/ml speci®c chemokine in a Boyden chamber chemotaxis assay. All antiserum titers were tested in direct ELISA and found to detect bound antigen at a dilution of 1:10 6 . HAM-56 monoclonal antibody to human macrophages was purchased from Enzo Diagnostics (New York, N.Y.). The relevant isotype antibody or pre-immune serum was used as the control for immunohistochemistry or chemotaxis experiments.
Immunohistochemical localization of chemokines or macrophages
Paran-embedded tumor and normal lung tissue were processed for immunohistochemical localization of CC chemokines, using a modi®cation of our previously described technique [40] . Brie¯y, tissue sections were de-waxed with xylene and rehydrated through graded concentrations of ethanol. Tissue nonspeci®c binding sites were then blocked by normal goat serum (normal rabbit serum for RANTES staining; BioGenex, San Ramon, Calif.). Tissue sections were then washed and incubated with primary antisera to human CC chemokines or human macrophages (1:500 dilution for rabbit antisera to MCP-1, MIP-1a, MIP-1b; 1:400 for goat anti-RANTES and pre-diluted HAM-56 antibody from Enzo diagnostics), or equal dilutions of pre-immune serum for chemokine antibodies. The tissue sections were washed and then incubated for 60 min with biotinylated secondary antibodies (BioGenex, San Ramon, Calif.). Sections were then washed twice in TRIS-buered saline and incubated with alkaline phosphatase conjugated to streptavidin (BioGenex, San Ramon, Calif.). Fast Red (BioGenex, San Ramon, Calif.) reagent was used for chromogenic localization of antigen in phosphatase-stained sections. After optimal color development, tissue sections were immersed in sterile water, counterstained in hematoxylin (macrophage-stained sections were counterstained lightly to facilitate cell counting), and cover-slipped, using an aqueous mounting solution.
Cytokine ELISA Antigenic MCP-1, MIP-1a, MIP-1b and RANTES were measured by a modi®cation of a double-ligand method, as previously described [7, 14] . Brie¯y,¯at-bottomed 96-well plates were coated with the appropriate polyclonal antibodies. Nonspeci®c binding sites were blocked with 2% bovine serum albumin in phosphatebuered saline. Test samples (undiluted and 1:10 diluted) were added (50 ll/well) for 1 h at 37°C. Plates were washed, biotinylated polyclonal antisera to human MCP-1, MIP-1a, MIP-1b, or RANTES were added at 50 ll/well, and the plates were incubated for 45 min at 37°C. The plates were then washed three times, streptavidin-peroxidase conjugate (Bio-Rad Laboratories, Richmond, Calif.) was added, and the incubation was continued for 30 min at 37°C. Plates were washed three times and chromogen substrate (Bio-Rad Laboratories, Richmond, Calif.) was added. The plates were incubated at room temperature to the desired absorbance, and the reaction was terminated with 50 ll/well 3 M H 2 SO 4 solution. Plates were read at 490 nm in an automated microplate reader (Bio-Tek Instruments Inc., Winooski, Vt.). Standards were dilutions of recombinant interleukins from 100 ng to 1 pg/ml (50 ll/well). This ELISA method consistently detected speci®c cytokine concentrations greater than 50 pg/ml in a linear fashion. All tissue homogenate specimens were run in parallel to determine the total protein content (Pierce, Rockford, Ill.), and results are expressed as nanograms of cytokine per milligram of protein.
Chemotaxis
In vitro monocyte chemotaxis was performed in modi®ed Boyden chambers (Neuroprobe. Cabin John, Md.) as previously described [20, 41, 42] . Peripheral blood mononuclear cells were isolated from heparinized whole blood by Ficoll-Hypaque gradient centrifugation. The bottom wells of blind-well chemotaxis chambers were ®lled with test samples (NSCLC tumor homogenate or normal lung) with either neutralizing CC chemokine antibody or control serum (1:500 dilution, heat-inactivated). Filters were placed over the wells and the top wells were ®lled with freshly isolated human peripheral blood mononuclear cells (normal donor, 3´10
6 cells/ml) [20, 41, 42] . Chambers were placed in humidi®ed, 37°C, 5% CO 2 incubators for 1.5 h. Filters were then removed, stained, and mounted on slides. Migrated cells were counted in ®ve high-power ®elds per well. Each condition was run in triplicate, and the experiments were repeated three times. Results were expressed as mean SEM of cells per high-power ®eld.
Statistical analysis
Data were analyzed on a Macintosh computer using the Statview 4.5 statistical package (Abacus Concepts Inc., Berkeley, Calif.). Student's t-test was used to compare groups of data in chemotaxis experiments. Results for tumor and normal tissue were compared by the Mann-Whitney U-test. Comparisons between histological subtypes of NSCLC were performed with the Kruskall-Wallis test. Data were expressed as means SEM. Data were considered statistically signi®cant if P values were less than or equal to 0.05.
Results
Macrophages are present throughout NSCLC tumors
In order to characterize the presence of macrophage in®ltration in NSCLC tumors, we performed immunohistochemical staining of the tumors with HAM-56 monoclonal antibody. Consistent with the ®ndings of other authors [13, 25] , we found a signi®cant number of in®ltrating macrophages in NSCLC tumors. Macrophages were found throughout all tumors in a diuse and heterogeneous distribution (Fig. 1) .
NSCLC homogenates are chemotactic for monocytes
To determine whether tumors were capable of actively recruiting mononuclear cells, we performed in vitro chemotaxis assays on tumor homogenates, using peripheral blood mononuclear cells from normal donors. Tumor homogenates were very potent in eliciting monocyte chemotaxis. Chemotaxis induced by adenocarcinoma and squamous carcinoma was 6.6-and 9.9-fold higher than that induced by control normal lung homogenate, standardized to total protein ( Fig. 2 , P < 0.001). Interestingly, the monocyte chemotactic activity of squamous cell carcinoma was 1.5-fold greater than that of adenocarcinoma (P = 0.05).
CC chemokine levels are increased in tumor tissue
Since the primary chemoattractants for mononuclear cells are CC chemokines, we hypothesized that levels of CC chemokines would be higher in NSCLC tumors than in normal lung tissue. Lung tissue homogenates were assayed for several CC chemokines by speci®c ELISA. Results were normalized to total protein (ng chemokine/ mg total protein) to allow for standardization of tumor samples compared to normal lung tissue. Our results demonstrated higher levels of CC chemokines in tumor tissue than in normal tissue (Table 1) . Speci®cally, mean levels of MCP-1 in tumor samples were 2.24 0.53 ng/ mg total protein, compared to 1.04 0.41 ng/mg found in normal tissue (P = 0.04). MIP-1a levels in tumor were 2.09 0.46 ng/mg compared to 1.05 0.41 in normal lung (P = 0.05). MIP-1b levels in tumor were 1.92 0.34 compared to 0.66 0.35 ng/mg in normal lung tissue (P = 0.005) and RANTES levels in tumor and normal tissue were 12.31 3.99 and 6.99 1.68 ng/mg respectively (P = 0.05). Subgroup analysis demonstrated higher levels of MIP-1a in squamous cell carcinoma than in adenocarcinoma, and a trend toward higher levels of other CC chemokines in squamous cell carcinoma than in adenocarcinoma.
We next employed immunohistochemical staining to localize antigenic CC chemokines in NSCLC tumors. Throughout all NSCLC tumors examined, chemokine immunoreactivity was predominantly associated with malignant cells, but also found in scattered stromal cells as well as in a pattern that suggested binding to the extracellular matrix (Fig.3) .
CC chemokine expression correlates with macrophage in®ltration
On the basis of the above ®ndings, we expected that the degree of tumor in®ltration by macrophages would Fig. 2 Monocyte chemotactic activity of normal lung tissue, as compared to a denocarcinoma and squamous carcinoma lung cancer tissue. *P < 0.01 for the comparison with normal lung, **P < 0.05 for the comparison between adenocarcinoma and squamous cell carcinoma correlate with the level of chemotactic cytokines present in the tumors. There was a highly signi®cant correlation between macrophage in®ltration and levels of the individual chemokine, MIP-1b, in the corresponding tumor (r 2 = 0.45, P = 0.03; data not shown). Levels of MCP-1 also correlated with macrophage in®ltration (r 2 = 0.50, P = 0.02; data not shown). However, there was no signi®cant correlation of macrophage in®ltration with MIP-1a and RANTES. When the numbers of macrophages per high power ®eld were compared with the sum of all the CC chemokine levels measured, there was a signi®cant and direct correlation (r 2 = 0.71, P = 0.001; Fig. 4) . Clinical follow-up data on mortality were available for 15 of the 16 patients in whom we assessed macrophage in®ltration. Interestingly patients who died (n = 7) had signi®cantly greater numbers of macrophages than did patients who remained free of recurrence (n = 8; 92.3 19.8 compared to 49.2 6.6 macrophages per high power ®eld, P<0.05; average follow-up time 76 months; Table 2) NSCLC-induced monocyte chemotaxis is mediated by speci®c CC chemokines In order to determine the contribution of CC chemokines to NSCLC-induced monocyte chemotaxis, speci®c neutralizing antibodies were employed in the chemotaxis assays. There was a marked dierence between adenocarcinoma and squamous cell carcinoma in the degree of inhibition of monocyte chemotaxis achieved with neutralizing antibodies (Fig. 5) . In the case of squamous cell carcinoma, the greatest inhibition of monocyte chemotaxis was seen with the addition of anti-MCP-1, whereas anti-MIP-1b was a more potent inhibitor of adenocarcinoma-induced monocyte chemotaxis. In addition, in contrast to squamous cell carcinoma, neutralization of MIP-1a had no eect on monocyte chemotaxis in samples of adenocarcinoma. Neutralization of RANTES had a modest inhibitory eect on mononuclear cell chemotactic activity of NSCLC.
Discussion
In the present study we evaluated macrophage in®ltra-tion of human bronchogenic carcinoma. We found that tumors were in®ltrated with macrophages in a diuse, but non-homogeneous fashion. In addition, homogenates of NSCLC induced potent monocyte chemotactic activity. Overall, levels of CC chemokines were higher in the NSCLC tumors than in normal lung tissue. Associated with this increase in CC chemokine expression, we found histological evidence that tumors were in®ltrated with macrophages to a degree that correlated with CC chemokine expression. Furthermore, we found that squamous cell carcinoma was associated with higher levels of MIP-1a than was adenocarcinoma. This trend was paralleled by the fact that squamous cell carcinoma homogenates elicited a greater monocyte chemotactic response than did adenocarcinoma homogenates. We then found that the monocyte chemotactic activity could Fig. 4 Correlation of macrophage in®ltration in histological sections of non-small-cell lung cancer (as assessed by HAM-56 immunostaining) with total CC chemokine levels (MCP-1, MIP-1a, MIP-1b, and RANTES) in the corresponding tumor homogenate (r 2 = 0.71, P = 0.001) Table 2 Clinical follow-up data on 15 patients in whom we assessed macrophage in®ltration. Patients who died (n = 7) had signi®cantly greater numbers of macrophages than did patients who remained free of recurrence (n = 8, 92. Monocyte chemotaxis induced by adenocarcinoma and squamous cell carcinoma lung cancer homogenates in the presence of speci®c neutralizing CC chemokine antibodies or control (normal rabbit serum, NRS). *P < 0.01 compared to normal rabbit serum (NRS), **P < 0.05 for the comparison between adenocarcinoma and squamous cell carcinoma be almost entirely inhibited by the addition of neutralizing antibodies to CC chemokines. Furthermore, MIP1b and MCP-1, the chemokines that correlated most strongly with histological macrophage in®ltration, also accounted for the majority of the chemotactic activity in NSCLC tumor homogenates. One caveat of our study is that the``normal lung tissue'' we used was derived from patients undergoing thoracotomy for lung cancer. While we did exclude tissue that was in®ltrated with in¯am-matory cells by histology, it is possible that the lungs of these patients, all former smokers, do not truly re¯ect`n ormal'' tissue levels. While we have not exhaustively evaluated the entire family of CC chemokines in relation to macrophage in®ltration of NSCLC tumors, it is clear from our data that members of this family are expressed in high levels in tumors in a biologically active form. We cannot exclude the possibility that the chemotactic activity detected in tumor homogenates represents both secreted and intracellular chemokines. There is evidence that some chemokines are bound to glycosaminoglycans in the extracellular matrix via the carboxy-terminal heparin-binding domain [45] . The detection of antigenic protein, therefore, does not con®rm secretion of the protein. However, the presence of a signi®cant number of in®ltrating macrophages suggests that tumors may actively recruit monocytes/macrophages into the local environment via expression of CC chemokines. Immunolocalization would suggest that the cells responsible for this CC chemokine expression are the malignant cells and scattered non-malignant cells within the stroma.
These ®ndings may also be consistent with a local activation of the immune system re¯ecting an attempt to mount a tumor-speci®c immune response. Alternatively, the expression of chemokines within tumors may serve to attract macrophages, which may then provide support for tumor growth by several possible mechanisms. For example, Polverini and co-workers have shown that tumor-associated macrophages are potently angiogenic when isolated from experimental rat tumors [35] . More recent studies have found a correlation between macrophage in®ltration and vessel density in ovarian [33] , breast [22] , and CNS malignancies [29] . Similarly, Acero and co-workers [1] found that macrophages actually promoted in vivo tumor formation in several murine sarcoma cell lines. If macrophages promote growth or a pro-angiogenic environment [37] , then expression of CC chemokines, and consequent macrophage in®ltration, may confer a survival advantage upon a population of tumor cells. That an in¯ammatory response may promote tumorigenesis is further supported by the ®ndings of Moore et al., which demonstrate that mice de®cient in TNFa are less susceptible to formation of skin tumors [26] . In this same study, the authors reported that mice with deletion of the gene for MCP-1 were also less susceptible to skin tumor initiation [26] .
While tumors may derive bene®ts from mononuclear cell in®ltration, it is also clear that some tumors can be successfully contained and eradicated by immune cells [12, 21, 34] . The key to this apparent paradox may be the capacity of some tumors to induce the in¯ux of one population of immune cells selectively, without recruiting those cells that may exert antitumor eects. Alternatively, some tumors may recruit immune cells, but inhibit their ability to eect an antitumor response. In support of this contention, Vitolo and colleagues have found that tumor-derived lymphocytes fail to express`p ro-in¯ammatory'' cytokines in situ, despite evidence that they retain their ability to do so ex vivo when isolated from tumors [44] . In parallel with this, we have previously reported that NSCLC tumors express significant levels of the immunomodulatory cytokines, IL-1 receptor antagonist and IL-10 [38, 39] . This phenomenon, combined with the shedding of soluble tumorspeci®c antigens [2, 10, 30, 31] and reduced cell-surface expression of class I MHC antigens [9, 43] , may provide the tumor with a defense against immune surveillance.
A possible mechanism allowing recruitment of a selective population of leukocytes is through the elaboration of appropriate chemotactic cytokines. The CC chemokine family is a group of cytokines that exert chemotactic and activating activity with a variety of immune cells including monocytes, lymphocytes, eosinophils, basophils, and stem cells. A great deal of contrasting evidence exists in the literature regarding the role or function of chemokines in malignancy. For example, some authors have found that increasing tumor cell expression of CC chemokines through various genetransfer strategies can lead to enhanced antitumor activity. Nakashima et al. have found that MIP-1a gene transfer into colon adenocarcinoma cells reduced the tumor-forming potential of these cells compared to mock-transfected cells [27] . Similarly, Rollins and colleagues [36] as well as Huang and co-workers [18] found that gene transfer of murine-JE/MCP-1 (a murine CC chemokine) suppressed the tumorigenic and metastatic potential of malignant cells. However, in a separate study, Hirose and colleagues found disparate eects of transfecting tumor cells with MIP-1a and MCP-1 on their ability to form tumors in nude mice [17] . In their study, transfection of tumor cells with MIP-1a was associated with a neutrophilic in¯ux, and with reduced ability to form tumors. However, gene transfer of either human or murine MCP-1 did not inhibit the tumorforming potential of these cells. In a related study by Botazzi and colleagues, transfer of the MCP-1 gene into melanoma cells had disparate eects on tumor growth, depending on whether the number of cells inoculated was high (antitumor eects predominated), or low (protumor eects predominated) [6] . In this same study, MCP-1-expressing melanoma cells were less susceptible to the antitumor eects of IL-2 therapy [6] .
In contrast to these strategies employing transfected tumor cells, our data, combined with previous work of other authors [5, 11, 28, 32] suggest that many tumors are already expressing signi®cant levels of chemotactic cytokines. For example, constitutive expression of MCP-1 has been reported in human ovarian carcinoma [28] and glioma [11] . Interestingly, MCP-1 and its related chemokines, MCP-2 and MCP-3, were all originally cloned from malignant cell lines [5, 32] . Recently there has been experimental evidence that chemokines play a role in polarizing T-helper immune responses along the Th1/Th2 axis. In particular, several authors have found that MCP-1 can promote the development of Th2 responses from naõÈ ve T cells [8, 16, 19, 23] . These ®ndings by other investigators suggest a mechanism of chemokine regulation of immune responses that a tumor might use to retard Th1-mediated antitumor responses. While this study was not designed to examine survival in relation to macrophage in®ltration, the ®nding that patients who subsequently died of recurrent malignancy had greater degrees of macrophage in®ltration in their tumors suggests that macrophages may be co-opted by tumors to support growth or metastasis.
Finally, recent work, using mice de®cient in either MCP-1 (JE) [15] , or its receptor CCR2 [4] , suggests that macrophages play an important role in animal models of atherosclerosis. While atherosclerosis and tumor growth may appear to be very diverse in pathophysiology, these interesting ®ndings suggest the importance of the monocyte/macrophage in disease states characterized by inappropriate tissue proliferation.
Given these contrasting data, it remains unclear whether expression of chemokines represents a feature of malignant cells that confers some survival advantage, or whether it represents an ineective eort on the part of the host immune system to mount an antitumor response. The goal of future studies in this area should be to determine the mechanism by which these chemokines are expressed in tumors, as well as more precisely de®ning the consequences of macrophage in®ltration in solid tumors.
